High throughput solubility measurement in drug discovery and development.
about
Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitorsSmall-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties.Advances in improving the quality and flexibility of compound management.Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 StudyUnderstanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesExploratory analysis of kinetic solubility measurements of a small molecule libraryRecent application of analytical methods to phase I and phase II drugs development: a review.Solubility at the molecular level: development of a critical aggregation concentration (CAC) assay for estimating compound monomer solubility.Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate.A three-stage biophysical screening cascade for fragment-based drug discovery.Development of a novel approach to enhance the solubility of ftibamzone formulation.Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase InhibitorsInvestigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach.Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.The future of microfluidic assays in drug development.Analytical technologies for real-time drug dissolution and precipitation testing on a small scale.Preclinical formulations: insight, strategies, and practical considerations.Principles and applications of Raman spectroscopy in pharmaceutical drug discovery and development.Practical approaches to resolving reactive metabolite liabilities in early discovery.Amorphous solid dispersions: a robust platform to address bioavailability challenges.Synthesis and evaluation of new polynuclear organometallic Ru(II), Rh(III) and Ir(III) pyridyl ester complexes as in vitro antiparasitic and antitumor agents.Cancer cell killing by Celecoxib: reality or just in vitro precipitation-related artifact?Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.Initial salt screening procedures for manufacturing ibuprofen.Biomimetic Design of Protein Nanomaterials for Hydrophobic Molecular Transport.Polymeric nanoparticles loaded with the 3,5,3'-triiodothyroacetic acid (Triac), a thyroid hormone: factorial design, characterization, and release kinetics.Practical High-Throughput Experimentation for ChemistsA surrogate for topical delivery in human skin: silicone membranes.In vivo brain microdialysis as a formulation-screening tool for a poorly soluble centrally acting drug.Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs.Evaluation of separate role of intestine and liver in first pass metabolism of budesonide in rat.Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs.Highly solvatochromic and tunable fluorophores based on a 4,5-quinolimide scaffold: novel CDK5 probes.Solubility and dissolution enhancement strategies: current understanding and recent trends.The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs
P2860
Q27678993-3DA08508-C6F7-4185-BC15-6987577DE62BQ30417779-E58DF117-37F7-4C71-AE1C-30783D20B59DQ33456643-A492904C-849A-4AE9-A078-2740BE2540C3Q33635992-4DFCD353-7900-4438-A10E-D7929F14F1DEQ33683206-F2E0F651-4C71-4D27-9CBE-F06CD67E93A6Q33922501-D53D269E-61DA-4BBB-AAC9-82404C2928A5Q33997398-D4000DA3-D9D2-4EA8-A87C-1F8E3C047F4FQ34197593-382790EC-2609-4637-BE99-27D1D9E2D7D1Q34260371-F99312B4-19B2-4F9A-A728-90322BA76B03Q35025905-04C33742-25C7-481A-9469-8BFC0688EB3EQ35676814-AC019B19-C4D8-4081-877A-EAFAFD74F9CDQ36059801-B0572364-0CBB-4363-A5E3-3529D77D8EA3Q36452404-79AB5B64-4F13-4FE1-8750-9BB9CD1B1E45Q37366206-19A0B933-0919-4BF5-A433-67BB7D52ADAEQ38089178-8B8E84AD-73C8-48EA-B0A6-91CA9A5A53FAQ38212289-CE3F3D4C-1670-498A-A21A-D2E2AFC752A7Q38219628-09624389-82F1-496D-9083-22B8B7775146Q38268561-C8030BC7-C053-497D-BA51-ED218D5191E2Q38269781-83EBBCBD-8B4A-4F5E-A00E-958E82605C38Q38358879-86CCD1FB-7F24-4CE0-A8D4-3942CE2CAAADQ39079789-765AF373-769A-4185-A875-964FD9ACA4B8Q39214848-BF01B61E-3038-49D9-A50E-F6D94B5FDFCEQ39780179-F9C64D46-233B-4386-8643-4544FBB31221Q39786216-08CBED18-DDE4-4F6E-B3D6-8BEF90CFC61EQ40028258-F3FCF157-50F1-46BC-A86E-C3E5A5826A33Q41851273-9716573F-8521-43B9-AFAE-2068A6C89B1DQ42055713-D3EE6063-62D2-46F0-A7EC-681D9B9B98BDQ42208730-7D2A6251-009B-4959-85BC-D218C9B2DD21Q45255508-B8ED388D-2C9E-45E9-9C35-A4500BBF597FQ46646546-ECAAB493-84BD-4105-A5B1-3D48F18BA0FCQ47139757-949DD9B0-9C04-4863-BECA-DA51DE9465D7Q47429728-EB120293-3EB6-4A5A-96A2-4B05E803A19BQ48166645-2D4E9631-1058-43C0-A877-0A98AC8DB921Q50235954-9FF8E65E-5FC3-439E-B51F-92B4C403F992Q51020710-DE3637C1-6E79-4E83-822C-29CCE947BD33Q51405119-ADBA5DE9-68DB-433A-B8BF-E1B4882D34ECQ57381486-F3769B5F-B2F9-4156-BFDC-D1B526D78216
P2860
High throughput solubility measurement in drug discovery and development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
High throughput solubility measurement in drug discovery and development.
@en
type
label
High throughput solubility measurement in drug discovery and development.
@en
prefLabel
High throughput solubility measurement in drug discovery and development.
@en
P1476
High throughput solubility measurement in drug discovery and development.
@en
P2093
Jochem Alsenz
Manfred Kansy
P304
P356
10.1016/J.ADDR.2007.05.007
P407
P577
2007-05-29T00:00:00Z